New study tracks Real-World impact of targeted radiation on prostate cancer Patients' daily lives

NCT ID NCT06517719

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 28 times

Summary

This study follows 500 men with metastatic castration-resistant prostate cancer who are receiving a radioactive drug called lutetium (177Lu) vipivotide tetraxetan. Researchers want to see how the treatment affects patients' quality of life, pain, and cancer progression in everyday medical practice. The goal is to understand the real-world benefits and side effects beyond clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Konstanz, Baden-Wurttemberg, 78464, Germany
Novartis Investigative Site
RECRUITING

Stuttgart, Baden-Wurttemberg, 70174, Germany
Novartis Investigative Site
RECRUITING

Munich, Bavaria, 81377, Germany
Novartis Investigative Site
RECRUITING

Regensburg, Bavaria, 93053, Germany
Novartis Investigative Site
RECRUITING

Würzburg, Bavaria, 97080, Germany
Novartis Investigative Site
RECRUITING

Cottbus, Brandenburg, 03048, Germany
Novartis Investigative Site
RECRUITING

Frankfurt (Oder), Brandenburg, 15236, Germany
Novartis Investigative Site
RECRUITING

Ludwigshafen, Germany, 67063, Germany
Novartis Investigative Site
RECRUITING

Marburg, Hesse, 35043, Germany
Novartis Investigative Site
RECRUITING

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site
RECRUITING

Dresden, Saxony, 01307, Germany
Novartis Investigative Site
RECRUITING

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site
RECRUITING

Halle, Saxony-Anhalt, 06120, Germany
Novartis Investigative Site
RECRUITING

Jena, Thuringia, 07740, Germany
Novartis Investigative Site
RECRUITING

Aachen, 52074, Germany
Novartis Investigative Site
RECRUITING

Augsburg, 86179, Germany
Novartis Investigative Site
RECRUITING

Berlin, 10249, Germany
Novartis Investigative Site
RECRUITING

Berlin, 12559, Germany
Novartis Investigative Site
RECRUITING

Berlin, 13125, Germany
Novartis Investigative Site
RECRUITING

Bielefeld, 33611, Germany
Novartis Investigative Site
RECRUITING

Bonn, 53105, Germany
Novartis Investigative Site
RECRUITING

Chemnitz, 09113, Germany
Novartis Investigative Site
RECRUITING

Dortmund, 44137, Germany
Novartis Investigative Site
RECRUITING

Dortmund, 44309, Germany
Novartis Investigative Site
RECRUITING

Erlangen, 91054, Germany
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

Fulda, 36043, Germany
Novartis Investigative Site
RECRUITING

Herford, 32049, Germany
Novartis Investigative Site
RECRUITING

Homburg, 66421, Germany
Novartis Investigative Site
RECRUITING

Magdeburg, 39120, Germany
Novartis Investigative Site
RECRUITING

Mainz, 55131, Germany
Novartis Investigative Site
RECRUITING

Nuremberg, 90419, Germany
Novartis Investigative Site
RECRUITING

Rostock, 18057, Germany
Novartis Investigative Site
RECRUITING

Trier, 54290, Germany
Novartis Investigative Site
RECRUITING

Tübingen, 72076, Germany
Novartis Investigative Site
RECRUITING

Ulm, 89081, Germany

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER